Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral Compression Fractures of (Suspected) Osteoporotic Origin. (EXPAND-US)

4 november 2026 bijgewerkt door: Amber Implants B.V.

A Prospective, Multicenter, Post-Market Clinical Study Collecting Real-World Data of the VCFix Spinal System in Stand-Alone Configuration for Vertebral Augmentation (EXPAND-US)

This study is designed as a prospective, post-market, multi-center, single-arm study to collect real-world data of the VCFix Spinal System used in US clinical practice.

Approximately 5 centers in the US will enroll subjects with VCF in a non-randomized fashion, and VCFix will be used within its cleared purpose and indications for use.

The study has been designed to be methodologically compatible with the EU EXPAND (CIP-VS02-EU) study, thereby aiming for the pooling of data to the EU study. Data pooling will be pursued only as a sensitivity analysis if pre-specified similarity criteria are met. The US study provides meaningful real-world evidence regardless of pooling feasibility.

The targeted patient population, assessment schedule, and study endpoints are therefore similar to those of the EU EXPAND study.

Studie Overzicht

Studietype

Observationeel

Inschrijving (Geschat)

30

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • New York
      • New York, New York, Verenigde Staten, 10467
        • Werving
        • Montefiore Medical Center
        • Contact:
          • Research Administrator
          • Telefoonnummer: (718) 920-6202
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73104
        • Nog niet aan het werven
        • University of Oklahoma Health Campus
        • Contact:
          • Research Project Manager
          • Telefoonnummer: (405) 271-8001
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19107
        • Nog niet aan het werven
        • Rothman Orthopaedics
        • Contact:
          • Clinical Research Coordinator
          • Telefoonnummer: (484) 335-2910

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

21 jaar tot 85 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Adult patients undergoing treatment with the VCFix Spinal System as part of standard clinical care for vertebral compression fractures. The study will enroll patients treated according to routine clinical practice and will collect real-world evidence on clinical outcomes, radiographic outcomes, and patient-reported outcomes following treatment.

Beschrijving

Inclusion Criteria:

  • 1. Subject is ≥ 21 to ≤ 85 years old. 2.

Single vertebral fracture which meets all of the following criteria:

  • Type A fractures from AO spine classification (compression injuries);
  • Vertebral fracture located in the thoracic and lumbar regions of the spine
  • Fracture age < 6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)
  • Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 60% based on radiographic evidence
  • Target VB has appropriate anatomy, i.e. suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery 3. Subject is diagnosed with, or has a suspected diagnosis of, severe osteoporosis, including low trabecular bone quality , and/or an oversized vertebral body as compared to implant size (e.g. relatively small pedicle requiring smaller implant size than desired for vertebral body size and/or fracture characteristics and location) 4. Subject has a NPRS back pain score of ≥5 5. Subject is a candidate for surgical intervention based on investigator opinion 6. Subject has a body Mass Index (BMI) < 35 7. Subject is mentally capable of complying with trial protocol requirements for the duration of the study 8. Subject can understand the risks and benefits of participating in the study and is able to provide written informed consent

Exclusion Criteria:

  1. Neoplasms with posterior involvement and/or presence of a mass within the spinal canal

  2. Non-mobile fractures (i.e., fracture is not recent (>6 weeks), bone marrow edema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction).

  3. Spondylolisthesis > Grade 1 at target vertebral body(s)

  4. Local kyphotic angle > 30°

  5. Any pre-existing vertebral fracture prior to the index fracture

  6. Previous spine surgery, balloon kyphoplasty or vertebroplasty, for any vertebral fracture

  7. Subjects that require anterior stabilization of the index fracture

  8. Fracture to the pedicle based on radiographic evaluation

  9. Spinal cord compression or canal compromise requiring decompression

  10. Severe back pain due to causes other than acute fracture with NPRS score > 5

  11. The subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)

  12. Pain due to any other condition that requires daily narcotic (opiates or opioids) medication

  13. Pre-existing neurological deficit, radiculopathy or myelopathy

  14. Pre-existing condition or significant co-morbidity:

    1. Uncontrolled diabetes (HbA1c >8%)
    2. Severe cardiopulmonary deficiencies
    3. Any other condition that would impact study outcome in the opinion of the investigator
  15. Irreversible coagulopathy or bleeding disorder

  16. Contraindications to both MRI and Computed Tomography (CT) imaging

  17. Concurrent participation in another clinical study which could potentially interfere with the outcome of this study

  18. A life expectancy less than the study duration or undergoing palliative care

  19. Subject non-ambulatory prior to fracture Allergy to any components of the device/instruments used during the procedure

  20. Allergy to any components of the device/instruments used during the procedure

  21. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection

  22. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfecta, Paget's disease, etc.)

  23. Any evidence of alcohol or drug abuse

  24. Ongoing long-term steroid therapy (steroid dose ≥30 mg /day for >3 months)

  25. The subject is currently on anti-cancer therapy or anti-HIV therapy

  26. Pregnancy or subjects with child-bearing potential that are unwilling to use contraception throughout the study duration.

  27. Patient known to be involved in medical litigation including Workmen's Compensation prior to the surgery

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Implant of the VCFix device per IFU

Patients with a (suspected) diagnosis of severe osteoporosis and a single vertebral compression fracture

The distinguishing features of this inetrvention reside in: 1. In situ adjustment and maintenance of the height and angle of the device that allows expansion of the fractured VB in the cranio-caudal direction to realign the vertebral endplates and correct kyphosis. 2. The complex titanium perforated structure with optimized surface roughness that allows possible bone attachment, thereby permitting natural healing of the bone and potentially providing more stability to the device and the treated vertebra over time. 3. The ability to connect the posterior to the anterior column of the spine through the pedicle screw component of the VCFix implant, therefore improving the biomechanical load distribution and consequently the ability to stabilize more severe fractures.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of serious adverse events (SAEs) related to the device and/or investigational procedure (safety)
Tijdsspanne: 1 month

Incidence of serious adverse events (SAEs) related to the device and/or investigational procedure within 30 days post-procedure. This includes SAEs resulting from mechanical malfunction, structural compromise, device failure, or loss of intended function, as well as events representing deviations from the device's intended medical purpose.

1 month
Vertebral fracture-related pain as assessed by the Numeric Pain Rating Scale (NPRS)
Tijdsspanne: 6 months

Difference in vertebral fracture-related pain from baseline 6 months post procedure measured by the 11-point (0 = no pain, 10 is worst pain) Numerical Pain Rating Scale (NPRS).

6 months
Functional disability, measured by the Oswestry disability index (ODI)
Tijdsspanne: 6 months

Difference in functional disability, measured by the Oswestry disability index (ODI) (0-100 scale, where 0 is no disability and 100 is bed bound), from baseline to 6 months post procedure.

6 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Vertebral height difference (anterior, midline, and posterior aspects)
Tijdsspanne: Post-Operative, 1Month FU, 6 Months FU, 12 Months FU

Vertebral height difference (anterior, midline, and posterior aspects) at PO (Post-OP), 1M FU, 6M FU and 12M FU as compared to baseline.

Post-Operative, 1Month FU, 6 Months FU, 12 Months FU
Kyphotic angle and Cobb angle improvement at Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.
Tijdsspanne: Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.

Kyphotic angle and Cobb angle improvement

Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.
Vertebral fracture-related pain as assessed by the Numeric Pain Rating Scale (NPRS)
Tijdsspanne: Discharge, 1, 3, 6 and 12 Months FU compared to baseline.

Difference in vertebral fracture-related pain from baseline to Discharge, 1, 3, 6 and 12 Months post procedure measured by the 11-point (0 = no pain, 10 is worst pain) Numerical Pain Rating Scale (NPRS).

Discharge, 1, 3, 6 and 12 Months FU compared to baseline.
Functional disability, measured by the Oswestry disability index (ODI)
Tijdsspanne: Discharge, 1, 3, 6 and 12 months FU

Improvement in function (measured by the 100-point Oswestry Disability Index (ODI)) at discharge, 1, 3, 6 and 12 months FU compared to baseline.

Discharge, 1, 3, 6 and 12 months FU
Health-related quality of life (HRQoL) measured by EuroQol 5-Dimension Scale (EQ-5D-5L) at 1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline
Tijdsspanne: 1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline

Improvement of Health-related quality of life (HRQoL)

1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline
Device-related serious adverse events assessed at 12- and 24- months post-procedure.
Tijdsspanne: 12 months FU, 24 months FU

Device-related serious adverse events

12 months FU, 24 months FU
All (per protocol reportable) adverse events assessed at 12- and 24- months post-procedure.
Tijdsspanne: 12 Months FU, 24 Months FU

All (per protocol reportable) adverse events assessed at 12- and 24- months post-procedure.

12 Months FU, 24 Months FU

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

4 oktober 2026

Primaire voltooiing (Geschat)

21 juli 2027

Studie voltooiing (Geschat)

31 december 2028

Studieregistratiedata

Eerst ingediend

31 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

4 november 2026

Eerst geplaatst (Werkelijk)

5 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren